As for clinical outcomes, in the T2DM group, there was a significant reduction in HbA1c (decreased by 1.01% to 1.02%, placebo-adjusted) and a clinically meaningful decrease in body weight of 3.26% to 3.51% after 12 weeks of treatment
10.1111/febs.13412 40 KempurajD.ThangavelR.NatteruP
[DOI] [PMC free article] [PubMed] [Google Scholar] 31.Fulop T., Koch C.A., Norris L.T., Rodriguez B., Szarvas T., Lengvarszky Z., et al
For TB-500, the TB-500 dosage calculator does the same
As mentioned, GLP-1RAs are increasingly used in the treatment of T2MD owing to their following advantages: lowering of the levels of blood glucose, reducing body weight, improving the function of islet, and exerting potential cardiovascular benefits (206)